Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
53,136,600
-
Number of holders
-
83
-
Total 13F shares, excl. options
-
34,764,459
-
Shares change
-
-6,261,514
-
Total reported value, excl. options
-
$21,657,477
-
Value change
-
-$4,297,866
-
Put/Call ratio
-
1.09%
-
Number of buys
-
33
-
Number of sells
-
-38
-
Price
-
$0.623
Significant Holders of ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO) as of Q1 2025
99 filings reported holding ALXO - ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share as of Q1 2025.
ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO) has 83 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 34,764,459 shares
of 53,136,600 outstanding shares and own 65.42% of the company stock.
Largest 10 shareholders include venBio Partners LLC (9,699,925 shares), Redmile Group, LLC (3,640,834 shares), TANG CAPITAL MANAGEMENT LLC (3,158,265 shares), BlackRock, Inc. (2,313,800 shares), VANGUARD GROUP INC (1,837,923 shares), BANK OF AMERICA CORP /DE/ (1,451,778 shares), Almitas Capital LLC (1,353,141 shares), ACADIAN ASSET MANAGEMENT LLC (1,296,331 shares), MILLENNIUM MANAGEMENT LLC (944,084 shares), and GEODE CAPITAL MANAGEMENT, LLC (770,907 shares).
This table shows the top 83 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.